UBS Group Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target upped by equities research analysts at UBS Group from $320.00 to $355.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s price target points to a potential upside of 10.82% from the company’s previous close.

A number of other brokerages have also issued reports on PODD. Piper Sandler raised their price target on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Jefferies Financial Group boosted their target price on shares of Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. upped their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $367.10.

Insulet Price Performance

PODD traded down $3.05 during trading on Friday, reaching $320.35. 336,152 shares of the company traded hands, compared to its average volume of 719,548. The company has a market cap of $22.55 billion, a P/E ratio of 97.28, a PEG ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet has a 12-month low of $230.05 and a 12-month high of $353.50. The firm has a fifty day simple moving average of $325.46 and a 200 day simple moving average of $308.84.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. During the same period in the prior year, the company earned $1.08 EPS. The company’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts forecast that Insulet will post 3.92 EPS for the current year.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently made changes to their positions in PODD. Vanguard Group Inc. raised its stake in Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after purchasing an additional 87,845 shares during the period. Geode Capital Management LLC grew its position in Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock worth $603,211,000 after acquiring an additional 58,309 shares during the period. American Century Companies Inc. lifted its position in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares during the last quarter. Groupama Asset Managment increased its position in shares of Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after acquiring an additional 3,759 shares during the last quarter. Finally, Norges Bank acquired a new stake in Insulet in the 2nd quarter valued at approximately $324,689,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.